Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Bases de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Vaccine ; 38(11): 2542-2550, 2020 03 04.
Artigo em Inglês | MEDLINE | ID: mdl-32044164

RESUMO

Chikungunya virus (CHIKV) is a mosquito-borne virus associated with arthritis and musculoskeletal pains. More than 2.9 million people worldwide have been infected with the virus within the last 1.5 decades; currently, there are no approved vaccines to protect against CHIKV infection. To assess the potential of using CHIKV peptides as vaccine antigens, we multivalently displayed CHIKV peptides representing B-cell epitopes (amino acids 2800-2818, 3025-3058, 3073-3081, 3121-3146, and 3177-3210), from E2 glycoprotein (Singapore strain), on the surface of a highly immunogenic bacteriophage Qß virus-like particle (VLP). We assessed the immunogenicity of CHIKV E2 amino acid 3025-3058 (including the other epitopes) displayed on Qß VLPs in comparison to the same peptide not displayed on VLPs. Mice immunized with the E2 peptides displayed on Qß VLPs elicited high-titer antibodies compared with the group immunized just with the peptide. However, sera from immunized mice did not neutralize CHIKV AF15561 (isolated from Thailand). The data suggest that Qß VLPs is an excellent approach to elicit high-titer CHIKV E2-protein antibodies at a lower dose of antigen and future studies should assess whether Qß-CHIKV E2 aa 2800-2818 VLPs and Qß-CHIKV E2 aa 3025-3058 VLPs can neutralize a Singapore Strain of CHIKV.


Assuntos
Allolevivirus , Anticorpos Antivirais/sangue , Febre de Chikungunya , Epitopos de Linfócito B/imunologia , Vacinas de Partículas Semelhantes a Vírus/imunologia , Vacinas Virais/imunologia , Animais , Febre de Chikungunya/prevenção & controle , Vírus Chikungunya , Camundongos , Testes de Neutralização , Singapura , Tailândia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA